ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Elicio Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.55−0.01 (-0.64%)

Close on Oct 19, 2026

Market cap: $29.83M
P/E (TTM): –
Dividend yield: –

Elicio Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	19	19	14	8.41	10	35	5.57
Cash & Short-Term Investments	19	19	14	8.41	10	35	5.57
Receivables	–	–	–	0	–	–	–
Prepaid Expenses & Other	0.75	1.90	2.73	2.92	1.69	7.69	–
Other Current Assets	–	–	–	0.25	0.50	0.36	–
Total Current Assets	19	21	16	11	91	42	–
Property, Plant & Equipment	0.30	0.48	0.72	1.15	0.45	0.16	–
Gross Property, Plant & Equipment	2.05	2.04	1.95	2.27	0.97	0.58	–
Accumulated Depreciation	-1.76	-1.55	-1.23	-1.12	-0.52	-0.43	–
Operating Lease Right-of-Use Assets	4.78	5.71	6.56	7.35	3.99	4.07	–
Other Long-Term Assets	–	–	–	0.06	0.11	0	–
Total Assets	26	28	27	23	97	47	–
Accounts Payable	0.67	1.04	4.37	2.81	4.71	5.58	–
Accrued Expenses	6.43	8.42	3.76	1.94	3.22	6.67	–
Current Portion of Leases	1.01	0.90	0.91	0.69	0.89	0.61	–
Deferred Revenue (Current)	0	1.17	0.69	1.44	2.30	3.94	–
Total Current Liabilities	8.11	12	9.76	6.87	11	107	–
Long-Term Debt	9.41	20	–	–	0	0.64	–
Long-Term Leases	4.09	5.11	6.01	6.79	3.48	3.85	–
Operating Lease Liabilities	5.11	6.01	6.92	3.48	4.37	4.46	–
Other Long-Term Liabilities	–	–	–	–	0	–	–
Total Liabilities	24	39	16	14	15	138	–
Total Debt	9.41	20	–	–	0	0.64	–
Preferred Stock	0	0	0	–	–	–	–
Common Stock	0.18	0.11	0.10	0.00	0.30	0.16	–
Additional Paid-In Capital	235	183	154	4.86	296	72	–
Retained Earnings	-234	-194	-142	-107	-215	-161	–
Treasury Stock	-0.15	-0.15	-0.15	0	0	-1.85	–
Comprehensive Income & Other	-0.13	-0.18	-0.20	0	-0.10	-0.33	–
Shareholders' Equity	1.64	-11	11	-102	-75	-90	-19
Total Equity	1.64	-11	11	-102	-75	-90	-19
Total Liabilities & Equity	26	28	27	23	97	47	–
Shares Outstanding(shares)	18	11	9.60	0.32	0.32	0.16	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 817.9%

Financial strength

Current ratio: 2.77
Debt to equity: 1.20
Debt to assets: 30.4%
Cash to current liabilities: 255.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.76
Dividend yield: –